These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23751955)

  • 1. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.
    Gadalla SM; Sales-Bonfim C; Carreras J; Alter BP; Antin JH; Ayas M; Bodhi P; Davis J; Davies SM; Deconinck E; Deeg HJ; Duerst RE; Fasth A; Ghavamzadeh A; Giri N; Goldman FD; Kolb EA; Krance R; Kurtzberg J; Leung WH; Srivastava A; Or R; Richman CM; Rosenberg PS; Toledo Codina JS; Shenoy S; Socié G; Tolar J; Williams KM; Eapen M; Savage SA
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1238-43. PubMed ID: 23751955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure.
    Ayas M; Nassar A; Hamidieh AA; Kharfan-Dabaja M; Othman TB; Elhaddad A; Seraihy A; Hussain F; Alimoghaddam K; Ladeb S; Fahmy O; Bazarbachi A; Mohamed SY; Bakr M; Korthof E; Aljurf M; Ghavamzadeh A
    Bone Marrow Transplant; 2013 Sep; 48(9):1168-72. PubMed ID: 23542225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Second Unrelated Donor Hematopoietic Stem Cell Transplant in a Patient With Dyskeratosis Congenital After First Graft Rejection.
    Giardino S; Faraci M; Lanino E; Morreale G; Terranova P; Palmisani E; Dufour C; Miano M
    Exp Clin Transplant; 2023 Apr; 21(4):368-374. PubMed ID: 28969530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.
    Nelson AS; Marsh RA; Myers KC; Davies SM; Jodele S; O'Brien TA; Mehta PA
    Biol Blood Marrow Transplant; 2016 May; 22(5):884-8. PubMed ID: 26845033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita.
    Elmahadi S; Muramatsu H; Kojima S
    Curr Opin Hematol; 2016 Nov; 23(6):501-507. PubMed ID: 27607446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review.
    Bhoopalan SV; Wlodarski M; Reiss U; Triplett B; Sharma A
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29177. PubMed ID: 34086408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita.
    Nishio N; Takahashi Y; Ohashi H; Doisaki S; Muramatsu H; Hama A; Shimada A; Yagasaki H; Kojima S
    Pediatr Transplant; 2011 Mar; 15(2):161-6. PubMed ID: 21176016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita.
    Vuong LG; Hemmati PG; Neuburger S; Terwey TH; Vulliamy T; Dokal I; le Coutre P; Dörken B; Arnold R
    Acta Haematol; 2010; 124(4):200-3. PubMed ID: 21042011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita.
    Güngör T; Corbacioglu S; Storb R; Seger RA
    Bone Marrow Transplant; 2003 Mar; 31(5):407-10. PubMed ID: 12634734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
    Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
    Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin.
    Ayas M; Al-Musa A; Al-Jefri A; Al-Seraihi A; Al-Mahr M; Rifai S; El-Solh H
    Pediatr Blood Cancer; 2007 Jul; 49(1):103-4. PubMed ID: 16317729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.
    Fioredda F; Iacobelli S; Korthof ET; Knol C; van Biezen A; Bresters D; Veys P; Yoshimi A; Fagioli F; Mats B; Zecca M; Faraci M; Miano M; Arcuri L; Maschan M; O'Brien T; Diaz MA; Sevilla J; Smith O; Peffault de Latour R; de la Fuente J; Or R; Van Lint MT; Tolar J; Aljurf M; Fisher A; Skorobogatova EV; Diaz de Heredia C; Risitano A; Dalle JH; Sedláček P; Ghavamzadeh A; Dufour C
    Br J Haematol; 2018 Oct; 183(1):110-118. PubMed ID: 29984823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.